Olema Pharmaceuticals (OLMA) Stock Forecast & Price Target

Compare

904 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

OLMA Analyst Ratings

Strong Buy

11 Buy

0 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Olema

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

OLMA Stock 12 Month Forecast

Average Price Target

$42.00

▲(67.73% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Olema Pharmaceuticals in the last 3 months. The average price target is $42.00 with a high forecast of $60.00 and a low forecast of $20.00. The average price target represents a 67.73% change from the last price of $25.04.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","61":"$61","16.75":"$16.75","31.5":"$31.5","46.25":"$46.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,16.75,31.5,46.25,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25,27.692307692307693,30.384615384615387,33.07692307692308,35.769230769230774,38.46153846153847,41.15384615384615,43.84615384615385,46.53846153846154,49.23076923076923,51.92307692307693,54.61538461538461,57.30769230769231,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25,26.307692307692307,27.615384615384617,28.923076923076923,30.23076923076923,31.53846153846154,32.84615384615385,34.15384615384615,35.46153846153846,36.769230769230774,38.07692307692308,39.38461538461539,40.69230769230769,{"y":42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25,24.615384615384617,24.23076923076923,23.846153846153847,23.46153846153846,23.076923076923077,22.692307692307693,22.307692307692307,21.923076923076923,21.53846153846154,21.153846153846153,20.76923076923077,20.384615384615383,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.21,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.83,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.97,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$42.00

Lowest Price Target$20.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kelsey Goodwin

Piper Sandler

$40

Buy

59.74%

Upside

Initiated

01/07/26

Olema Oncology initiated with an Overweight at Piper SandlerOlema Oncology initiated with an Overweight at Piper Sandler

Yigal Nochomovitz

Citi

$60

Buy

139.62%

Upside

Assigned

01/06/26

Citi adds 'upside 90-day catalyst watch' on Olema OncologyCiti adds 'upside 90-day catalyst watch' on Olema Oncology

Michael Yee

UBS

$45

Buy

79.71%

Upside

Initiated

01/06/26

Olema Oncology initiated with a Buy at UBSOlema Oncology initiated with a Buy at UBS

Anupam Rama

J.P. Morgan

Buy

―

Reiterated

12/11/25

J.P. Morgan Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)

Emily Bodnar

H.C. Wainwright

$36→$45

Buy

79.71%

Upside

Reiterated

12/11/25

Promising Potential of Olema Pharmaceuticals' Palazestrant in Transforming ER+/HER2- Breast Cancer Treatment

Matthew Biegler

Oppenheimer

$45→$48

Buy

91.69%

Upside

Reiterated

12/11/25

Oppenheimer Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)

Richard Law CFA

Goldman Sachs

$26→$38

Buy

51.76%

Upside

Reiterated

12/11/25

Olema Oncology price target raised to $38 from $26 at Goldman SachsOlema Oncology price target raised to $38 from $26 at Goldman Sachs

Sam Slutsky

LifeSci Capital

$39

Buy

55.75%

Upside

Reiterated

12/10/25

Positive Outlook for Olema's OPERA-02 Trial Based on Roche's Promising Giredestrant Data

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

12/10/25

Clara Dong

Jefferies

$43

Buy

71.73%

Upside

Reiterated

12/10/25

Buy Rating for Olema Pharmaceuticals Driven by Promising Oral SERD Potential in Breast Cancer Treatment

Bradley Canino

Guggenheim

$20

Buy

-20.13%

Downside

Reiterated

11/18/25

Guggenheim Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kelsey Goodwin

Piper Sandler

$40

Buy

59.74%

Upside

Initiated

01/07/26

Olema Oncology initiated with an Overweight at Piper SandlerOlema Oncology initiated with an Overweight at Piper Sandler

Yigal Nochomovitz

Citi

$60

Buy

139.62%

Upside

Assigned

01/06/26

Citi adds 'upside 90-day catalyst watch' on Olema OncologyCiti adds 'upside 90-day catalyst watch' on Olema Oncology

Michael Yee

UBS

$45

Buy

79.71%

Upside

Initiated

01/06/26

Olema Oncology initiated with a Buy at UBSOlema Oncology initiated with a Buy at UBS

Anupam Rama

J.P. Morgan

Buy

―

Reiterated

12/11/25

J.P. Morgan Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)

Emily Bodnar

H.C. Wainwright

$36→$45

Buy

79.71%

Upside

Reiterated

12/11/25

Promising Potential of Olema Pharmaceuticals' Palazestrant in Transforming ER+/HER2- Breast Cancer Treatment

Matthew Biegler

Oppenheimer

$45→$48

Buy

91.69%

Upside

Reiterated

12/11/25

Oppenheimer Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)

Richard Law CFA

Goldman Sachs

$26→$38

Buy

51.76%

Upside

Reiterated

12/11/25

Olema Oncology price target raised to $38 from $26 at Goldman SachsOlema Oncology price target raised to $38 from $26 at Goldman Sachs

Sam Slutsky

LifeSci Capital

$39

Buy

55.75%

Upside

Reiterated

12/10/25

Positive Outlook for Olema's OPERA-02 Trial Based on Roche's Promising Giredestrant Data

Tyler Van Buren

TD Cowen

Buy

―

Reiterated

12/10/25

Clara Dong

Jefferies

$43

Buy

71.73%

Upside

Reiterated

12/10/25

Buy Rating for Olema Pharmaceuticals Driven by Promising Oral SERD Potential in Breast Cancer Treatment

Bradley Canino

Guggenheim

$20

Buy

-20.13%

Downside

Reiterated

11/18/25

Guggenheim Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Olema Pharmaceuticals

1 Month

xxx

Success Rate

11/18 ratings generated profit

Average Return

+5.31%

initiated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.11% of your transactions generating a profit, with an average return of +5.31% per trade.

3 Months

xxx

Success Rate

11/17 ratings generated profit

Average Return

+47.84%

reiterated a xxx

rating 28 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.71% of your transactions generating a profit, with an average return of +47.84% per trade.

1 Year

Emily BodnarH.C. Wainwright

Success Rate

18/29 ratings generated profit

Average Return

+172.47%

reiterated a buy rating 28 days ago

Copying Emily Bodnar's trades and holding each position for 1 Year would result in 62.07% of your transactions generating a profit, with an average return of +172.47% per trade.

2 Years

xxx

Success Rate

11/13 ratings generated profit

Average Return

+170.95%

reiterated a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 84.62% of your transactions generating a profit, with an average return of +170.95% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OLMA Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, OLMA has received 22 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. OLMA average Analyst price target in the past 3 months is 42.00.

Each month's total comprises the sum of three months' worth of ratings.

OLMA Financial Forecast

OLMA Earnings Forecast

Next quarter’s earnings estimate for OLMA is -$0.52 with a range of -$0.65 to -$0.44. The previous quarter’s EPS was -$0.49. OLMA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year OLMA has Performed in-line its overall industry.

No data currently available

OLMA Sales Forecast

Next quarter’s sales forecast for OLMA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. OLMA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year OLMA has Performed in-line its overall industry.

OLMA Stock Forecast FAQ

What is OLMA’s average 12-month price target, according to analysts?

Based on analyst ratings, Olema Pharmaceuticals’s 12-month average price target is 42.00.

What is OLMA’s upside potential, based on the analysts’ average price target?

Olema Pharmaceuticals has 67.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is OLMA a Buy, Sell or Hold?

Olema Pharmaceuticals has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.

What is Olema Pharmaceuticals’s price target?

The average price target for Olema Pharmaceuticals is 42.00. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $20.00. The average price target represents 67.73% Increase from the current price of $25.04.

What do analysts say about Olema Pharmaceuticals?

Olema Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of OLMA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Olema Pharmaceuticals (OLMA) Stock Forecast & Price Target

OLMA Analyst Ratings

OLMA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Olema Pharmaceuticals

OLMA Analyst Recommendation Trends

OLMA Financial Forecast

OLMA Earnings Forecast

OLMA Sales Forecast

OLMA Stock Forecast FAQ

Detailed List of Analyst Forecasts